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Summary
Objective: To evaluate the efﬁcacy of preparations with avocadoesoybean unsaponiﬁables (ASUs) in osteoarthritis (OA) patients using
meta-analysis on randomized controlled trials (RCTs).
Method: RCTs from systematic searches were included if they explicitly stated that hip and/or knee OA patients were randomized to either
ASU or placebo. The co-primary outcome was reduction in pain and Lequesne index, leading to effect size (ES), calculated as the standard-
ized mean difference. As secondary analysis, the number of responders to therapy was analyzed as odds ratios (ORs). Restricted maximum
likelihood methods were applied for the meta-analyses, using mixed effects models.
Results: Four trials e all supported by the manufacturer e were included, with 664 OA patients with either hip (41.4%) or knee (58.6%) OA
allocated to either 300 mg ASU (336) or placebo (328). Average trial duration was 6 months (range: 3e12 months). Though based on hetero-
geneous results, the combined pain reduction favored ASU (I 2¼ 83.5%, ES¼ 0.39 [95% conﬁdence intervals: 0.01e0.76], P¼ 0.04). Applying
the Lequesne index also favored ASU (I 2¼ 61.0%, ES¼ 0.45 [0.21e0.70], P¼ 0.0003). Secondarily, the number of responders following ASU
compared to placebo (OR¼ 2.19, P¼ 0.007) corresponded to a number needed to treat of six (4e21) patients.
Conclusions: Based on the available evidence, patients may be recommended to give ASU a chance for e.g., 3 months. Meta-analysis data
support better chances of success in patients with knee OA than in those with hip OA.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Musculoskeletal diseases are prevalent and their impact is
pervasive, affecting all age groups, and the associated
physical disability is an enormous burden on individuals
and society1,2. The socio-economic cost due to musculo-
skeletal conditions is huge, predominantly due to back
pain, osteoarthritis (OA) and rheumatoid arthritis (RA)2.
Pain is the major symptom in most arthritis patients3, and
is also the most important determinant of disability in pa-
tients with OA4. The prevalence of painful disabling knee
OA in people over 54 years living in the United Kingdom
is 10%, and 25% of these are severely disabled5,6. With an
estimated prevalence of 3e11% in Western populations
over 35 years, hipOA is the second-most frequentOA in large
joints7. Current OA treatment aims at alleviating pain symp-
toms in different ways8,9. With rough categorization, the1This study was supported by grants from the Oak Foundation
and Frederiksberg Hospital, Copenhagen Hospital Corporation.
*Address correspondence and reprint requests to: Professor
H. Bliddal, The Parker Institute, Frederiksberg Hospital, DK-2000
F, Denmark. Tel: 45-38164151; Fax: 45-38164159; E-mail:
henning.bliddal@frh.regionh.dk
Received 21 June 2007; revision accepted 1 October 2007.
399treatment is one of three types: non-pharmacological inter-
vention, pharmacological treatment, or invasive/surgical in-
tervention (including intra-articular injections, lavage, and
arthroplasty)6,7,9.
Complementary or alternative therapies (including nutra-
ceuticals) for OA are commonly used, and it is therefore
important that health care providers are aware of the evi-
dence supporting the claims10. Available evidence would
be easier to translate into clinical practice if the available
(and published) data were analyzed and presented using
an unbiased meta-analytic approach11,12. One proposed
nutraceutical, which has shown promising results in OA
patients, is avocadoesoybean unsaponiﬁables (ASUs).
Currently, the only ASU mixture investigated is made up
of unsaponiﬁable fractions of one-third avocado oil and
two-third soybean oil. Preclinical studies of ASU have shown
some anti-OA properties. In vitro, ASU is seen to have an in-
hibitory effect on interleukin-1 (IL-1) and a stimulating effect
on collagen synthesis in articular chondrocyte cultures13.
Data support the notion of ASU preparations as potent inhib-
itors of the production of IL-8 and prostaglandin E2 (PGE2)
by human articular chondrocytes14. In vitro data have shown
ASU to stimulate aggrecan and matrix component synthe-
sis, reduce catabolic and pro-inﬂammatory mediator produc-
tion by human osteoarthritic chondrocytes, and partially
400 R. Christensen et al.: Symptomatic efﬁcacy of ASU in OA patientscounteract the inhibitory effect of IL-1 (possibly via the pro-
duction of transforming growth factor beta (TGF-b)) and
growth factors associated with cartilage homeostasis15,16.
Accordingly, ASU seems to prevent the osteoarthritic osteo-
blast-induced inhibition of matrix molecule production, sug-
gesting that this compound may promote OA cartilage
repair by acting on subchondral bone osteoblasts17. Ernst
reviewed the available data on the efﬁcacy of ASU in OA pa-
tients and concluded that the majority of rigorous trials sug-
gest that ASU is effective in the symptomatic treatment of
OA, although the only long-term trial was largely negative,
and thus more research would be justiﬁed18. Ernst’s conclu-
sion corresponds to a review (in Danish) by Angermann,
which concludes that the available studies indicate that
ASU has an effect on the symptoms of knee and hip OA,
but no effect on the structural changes occurring with OA19.
We carried out a systematic review with a meta-analysis
of the available randomized controlled trials (RCTs)20 of
studies applying ASU in the symptomatic treatment of OA.
Our primary aim was to obtain an up-to-date evidence
based analysis which would provide a detailed view of the
symptomatic activity of ASU used in the treatment of knee
and hip OA21,22. Our secondary aim was to investigate
possible causes behind the statistical heterogeneity, em-
phasizing clinical heterogeneity across the included stud-
ies24. We used meta-regression analyses25 to implement
clinical arguments, which could result in clinical inference26.MethodsRETRIEVAL OF PUBLISHED STUDIESRCTs of ASU treatment vs placebo were identiﬁed by means of a system-
atic literature search in the following bibliographic databases: Medline via
PubMed (mid 1950s to Feb. 19, 2007), EMBASE via WebSpirs (1980 to
Feb. 19, 2007), CINAHL via WebSpirs (1982 to Feb. 19, 2007), BiosisPre-
views via WebSpirs (1980 to Feb. 19, 2007), Web of Science (1945e54 to
Feb. 19, 2007), Sciﬁnder (1907 to Feb. 19, 2007), Scopus (1966 to Feb.
19, 2007), and the Cochrane Library (1966 to Jan. 31, 2007). This was fol-
lowed by searches of reference lists of original reports and review articles,Potentially relevant studies identified and
screened for retrieval (k
0
= 20)
17-19,55-71
Trials retrieved for more detailed
evaluation (k
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= 9)
Studie
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Fig. 1. Flow of RCTs includedretrieved through the described searches. Finally, we searched conference
abstracts over the past 2 years via the established international societies
of rheumatology, i.e., the OsteoArthritis Research Society International
(OARSI), EUropean League Against Rheumatism (EULAR) and the Ameri-
can College of Rheumatology (ACR).
The search strategy consisted of the relevant keywords/MESH words for
OA combined with any combination of ASU, soy or avocado for wide cover-
age and to limit the search to controlled studies to take into account that ran-
domization is not always clearly deﬁned via keywords, and that some
controlled studies may be of interest despite lack of proper randomization.
With the awareness of a higher proportion of noise in the searches, titles
and abstracts were reviewed for possible RCTs, and full text references
were obtained for further scrutiny where relevant.INCLUSION AND EXCLUSION CRITERIAWe included RCTs comparing a preparation of both avocado and soy-
bean extracts with a (double masked) placebo intervention. Studies were
selected if the included patients were described as having clinical or radio-
graphic evidence of OA. Two reviewers (RC and HB) crosschecked and
agreed on diagnostic criteria in each trial. We excluded studies in conditions
such as non-OA joint pain, RA, pain due to surgery or injury, and studies with
mixed patient groups such as those with both OA and RA, unless the sub-
group data for OA were available. No language restrictions applied.QUALITY ASSESSMENTThe quality of studies was assessed based on randomization, masking
and withdrawal. The complete reports of the RCTs that were selected for
inclusion in the meta-analysis were scored by two reviewers for quality
(RC and EMB), using a validated instrument27. The score was given as fol-
lows: if the study was described as randomized (þ1); if the study was
described as double masked (þ1); and if there was a (detailed) description
of withdrawals and drop-outs (þ1). In addition, if the random allocation and
the double blinding were properly described and appropriately put into prac-
tice, each item received one point extra. Conversely, if the methods (random-
ization and masking) were not considered appropriate, one point was
subtracted from each item.DATA EXTRACTIONTwo reviewers (RC and EMB) undertook data extraction independently.
Disagreements were resolved by discussion. A customized form was used
to record authors of the study, year of publication, trial design, study length,s excluded because of:
ew articles (k
01
= 10)18,19,59,60,62,64,65,68-70
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401Osteoarthritis and Cartilage Vol. 16, No. 4T B M A L C anumber of patients randomized (Ntotal), number of patients in each group
included in the intention-to-treat (ITT) individual study statistical tests (nE
and nC), average patient age, sex, site of OA (knee, hip or both) handled
as the fraction (%) of patients with OA in the hip. For each of the continuous
outcomes extracted, the level at baseline was estimated for the following:
weighted-mean KellgreneLawrence (KL) (radiographic) score, body mass
index (BMI), pain, and the Lequesne index.OUTCOME MEASURESThe primary outcome measure was the magnitude of pain reduction28
with ASU compared to placebo. In addition, we looked at other outcome
measures in rheumatology (OMER) ACT-III relevant outcomes21, and the
Lequesne index29, applied in all the individual RCTs, were used to evaluate
the patients’ global assessment22. Finally, we extracted the reported number
of responders per group after each intervention, ASU or placebo, respec-
tively, for each included study.STATISTICAL ANALYSISFor each of the continuous outcomes (pain and the Lequesne index), we
calculated the z-statistics based on the available data, using standard formu-
lae30,31. Based on these z-statistics and the number of observations in each
group, we estimated the standardized mean difference (SMD)32, which was
applied as effect size (ES): the ratio of the treatment effect to the pooled
standard deviation of these differences31,33. The variance (associated with
the SMD value) was estimated based on the individual study SMD and the
number of patients included (nE and nC)
32,34. Clinically, ES 0.2 is consid-
ered small, ES 0.5 is moderate (and would probably be recognized clini-
cally35), and ES 0.8 is large6,7. The odds ratio (OR) was estimated for
the dichotomous efﬁcacy data36, i.e., based on the number of responders
in each group. Based on the combined OR, we estimated the number
needed to treat [NNT, with 95% conﬁdence intervals (CI)], as it enables di-
rect translation into clinical practice37,38. To adjust for the individual study
‘‘baseline risk’’37, we applied the weighted, pooled control event-rate39,40 ap-
plying visual Rx41,42. To combine the individual study results, we carried out
meta-analyses, using SAS software34 (version 9.1.3), applying restricted
maximum likelihood (REML) within a mixed effects model setting43. Maxi-
mum likelihood approaches in meta-analysis44,45 enable the meta-analyst
to print the solutions: the EB estimates46,47. This methodology has previ-
ously been informally validated and described in detail32,48. We examined
heterogeneity between trials with a standard Q-test statistic, which follows
a c2 distribution49, leading to the I 2 statistic, i.e., the proportion of variance
unexplained50,51. The I 2 index quantiﬁes the impact50, rather than the extent
(i.e., t2)52 of heterogeneity in a meta-analysis. It is important to include a pri-
ori deﬁned ways to investigate potential sources of clinical heterogeneity,
even when applying a random effects model by default23. If this is not
done, it might result in the exploratory investigations affecting the overall
conclusions drawn24, based on spurious chance ﬁndings. We assessed
the extent to which study level variables were associated with the ES and
(loge) OR by ﬁtting multiple REML based meta-regression models
23,25. A pri-
ori, we deﬁned a relevant study level covariate48,53 as one that would de-
crease all three I 2 statistics (one for each of the separate outcomes)54 as
the between study variance for each outcome decline as a consequence
of inclusion in the (mixed effects) statistical model. Although tempting, cova-
riates with errors around the estimate (e.g., average age) would not be char-
acterized as a detailed trial feature, thus predictive inference based on these
should generally be discouraged in study level meta-regression analysis26.ResultsCHARACTERISTICS OF TRIALSThe quality of reporting of meta-analyses (QUOROM)
recommended ﬂowchart20 in Fig. 1 displays the eligibility
details of the studies identiﬁed by the combined search
strategy. After removing abstracts from studies with obvi-
ously irrelevant objectives/designs, a restricted set of po-
tentially relevant articles and possibly relevant reviews
were scrutinized and reviewed (k0¼ 20) according to the in-
clusion/exclusion criteria17e19,55e71. Among these potential
papers for inclusion, the majority was excluded for the fol-
lowing reasons: one paper was a review article assessing
the placebo effect across several anti-arthritic preparations
(among which ASU)59, nine of the papers were reviews fo-
cusing on herbs (and ASU) in general18,19,60,62,64,65,68e70,
-1.2 -1.0 -0.8 -0.6 -0.4 -0.2 0.0 0.2 0.4 0.6 0.8 1.0 1.2
ES: Pain (SMD)
A
Blotman (1997)
Maheu (1998)
Appelboom (2001)
Lequesne (2002)
Pooled (REML)
ES:0.39 (95% CI: 0.01 to 0.76) 
Z = 2.03, P = 0.042 
Q = 18.15 (P<0.001) 
I
2
 = 83.5%
B
Favors Placebo Favors ASU
402 R. Christensen et al.: Symptomatic efﬁcacy of ASU in OA patientsand one article was based on an in vitro study17. Accord-
ingly, these papers were excluded after thorough reading
and examined for further studies that might be revealed in
their references. Of the nine remaining, potentially possible
RCTs: one study was excluded due to not applying a rele-
vant intervention/control group71, another paper used
a soy-only preparation66, and one (although large scale)
study was omitted due to use of an open-label (non-ran-
domized) design, without a proper control group67. After
a second reading, we decided to exclude yet two ab-
stracts55,56, as they presented preliminary data from RCTs
later published in full58,63.
As a result we obtained four trials57,58,61,63 that fulﬁlled
the inclusion criteria and were included in the meta-analy-
sis. All studies were supported by the Laboratoires Expan-
science, Courbevoie, France: applying PIASCLEDINE300
(avocado:soybean ratio 1:2). These four studies represent
664 OA patients with hip (41.4%) and knee (58.6%) joint
affected, randomly allocated to either one capsule a day
containing 300 mg ASU (nE¼ 336) or an identical masked
placebo (nC¼ 328). The (Ntotal) weighted-mean trial dura-
tion corresponded to a 6-month trial on average, generally
assessed in high quality studies (weighted-average Jadad:
4.5). Patient characteristics are presented in Table I.Blotman (1997)
EFFICACY-1.0 -0.8 -0.6 -0.4 -0.2 0.0 0.2 0.4 0.6 0.8 1.0
ES: Lequesne Index (SMD)
Maheu (1998)
Appelboom (2001)
Lequesne (2002)
ES: 0.45 (95% CI: 0.21 to 0.70)
Z = 3.64, P = 0.0003 
Q = 7.70 (P=0.053) 
I
2
 = 61.0%
Pooled (REML)
0.10 1.00 10.00
OR (Self-reported responders)
Q = 9.63 (P=0.022) 
I
2
 = 68.9% 
C
Blotman (1997)
Maheu (1998)
Appelboom (2001)
Lequesne (2002)
Pooled (REML)
OR: 2.19 (95% CI: 1.24 to 3.86)
Z = 2.69, P = 0.007 
Fig. 2. Forest-plots of trials comparing ASU with placebo on pain,
Lequesne, and the number of responders to treatment, respec-Figure 2(A) shows the ES in pain reduction with ASU vs
placebo. Pooling the data from the four individual trials re-
porting pain as an explicit outcome produced a REML
based (i.e., random effects model) combined ES of 0.39
(95% CI: 0.01e0.76, P¼ 0.04), supporting efﬁcacy of
ASU as opposed to placebo. The result is based on studies
showing a severe impact of heterogeneity (I 2¼ 83.5%) with
a between study variance of more than zero (t2 0.1202).
Therefore possible sources of heterogeneity need to be in-
vestigated. Figure 2(B) shows the ES in the algo-functional
Lequesne index reduction with ASU vs placebo. Pooling the
data from the four individual trials reporting Lequesne as an
explicit outcome produced a highly signiﬁcant REML based
(i.e., random effects model) combined ES of 0.45 (95% CI:
0.21e0.70, P¼ 0.0003). This strongly supports efﬁcacy of
ASU treatment as opposed to placebo. The result is based
on studies showing a large impact of heterogeneity
(I 2¼ 61.0%) with a between study variance of more than
zero (t2 0.0380). Accordingly, possible sources of hetero-
geneity should therefore be investigated. Figure 2(C) shows
the OR corresponding to the number of patients responding
to treatment, that is, the number (rE and rC) each individual
RCT explicitly reports on responders to treatment. Pooling
the data from the four individual trials produced a signiﬁcant
REML based (i.e., random effects model) combined OR of
2.19 (95% CI: 1.24e3.86, P¼ 0.007), in favor of ASU op-
posed to placebo, as more patients responded to therapy.
By adjusting this OR with the weighted, pooled control
event-rate of 33.4%, data correspond to a NNT of six
(95% CI: 4e21) patients. The result is based on studies
showing a large impact of heterogeneity (I 2¼ 68.9%) with
a between study variance of more than zero
(t2 0.2324). Accordingly, possible sources of heterogene-
ity should be investigated.tively; size of every circle is proportional to the precision of each
efﬁcacy estimate.EXPLORING CLINICAL HETEROGENEITYAs presented in Table II, the available study level covari-
ates reduce (or increase) the between study variance in
Table II
Statistical data explaining possible clinical reasons for heterogeneity among available study level covariates
Outcome ES: pain ES: Lequesne loge(OR): responders
Variable t2¼ 0.120 I 2¼ 83.5% t2¼ 0.038 I 2¼ 61.0% t2¼ 0.232 I 2¼ 68.9% (%)
%Hip OA 0 0 0 0 0 0
Jadad QS 0.039 27.1 0.061 98.4 0.324 96.2
Duration 0.074 51.1 0.004 6.4 0 0
Age 0 0 0.010 16.6 0.019 5.5
%Females 0.011 7.8 0 0 0 0
BMI 0.015 10.7 0.051 82.2 0.315 93.5
KL score 0.160 >100 0.056 89.4 0.398 >100
Pain 0.010 68.2 0 0 0.065 19.3
Lequesne 0.187 >100 0.068 >100 0.331 98.0
403Osteoarthritis and Cartilage Vol. 16, No. 4several ways. This is why we focused solely on covariates
that are able to reduce the impact of heterogeneity for
all outcome measures (pain, Lequesne, and number of re-
sponders) simultaneously: %patients with hip OA, duration
of the individual trial, average patient age, %females in
the included population, and ﬁnally the average level of
pain at baseline. The covariates: ‘‘average patient age’’
and the ‘‘average level of pain’’ in the four existing trials
had very similar values; hence they would probably be irrel-
evant to explain the heterogeneity between trials, except for
possible cases where individual patient data (IPD) meta-
analysis is applicable. Based on these post hoc statistical
considerations, details on the joint affected and study dura-
tion were considered applicable for clinical practice. These
were included in the explicit post hoc meta-regression anal-
yses presented in Fig. 3. Please see the Appendix for
a detailed description of EB estimates after inclusion of
both covariates simultaneously.Discussion
Trials applying the ASU preparation from Laboratoires
Expanscience (PIASCLEDINE300) for knee or hip OA col-
lectively demonstrated small to moderate treatment effects
on symptoms (i.e., pain and Lequesne index). Patients
receiving ASU were twice as likely to respond to treatment
than patients allocated to placebo. The pooled ES for pain
reduction comparing ASU to placebo was 0.39, which
according to current European standards represents a mod-
est but clinically signiﬁcant treatment beneﬁt from ASU6,7.
Translated into an average European knee and hip OA
patient72,73, this estimate would correspond to a 6.3
(10.7%) and 6.4 (11.3%) mm visual analog scale (VAS)
pain reduction, respectively. Our secondary analysis
showed that patients prescribed ASU will be more likely re-
spond to therapy, than patients treated with placebo. These
data indicate that on a major public health scale2, one pa-
tient of six treated with ASU will beneﬁt from the treatment.
Clinical trials and meta-analyses have mostly addressed
the question of how well a treatment works overall. Both
these approaches, while useful in estimating a population
effect, do not show how to treat individuals26; patients of-
ten respond differently to treatment. To address this diver-
sity, meta-analyses need to evolve from simple pooling to
multidimensional exploration, creating response surface
models to summarize evidence along multiple covariatesof interest74. As presented in the Appendix, EB estimates
indicated that after 6 months’ ASU treatment, knee OA
patients would experience a large clinical effect on pain
reduction (ES: 0.99 [0.54e1.44]), whereas the same sta-
tistical model revealed that hip OA patients might not
experience any pain relief after ASU therapy (ES: 0.44
[1.05eþ0.17]). The clinician will typically be interested
in the target joint rather than the sex of the patient. We
admit though that knee OA may be associated with fe-
male gender in contrast to hip OA in males75.
How is this diversity possible? The majority of rigorously
selected individual trial data available to date, suggests
that ASU is effective for the symptomatic treatment of
OA57,58,61 even though the only long-term (hip OA only)
trial63 had a largely negative result18. To assess the clinical
question we might turn to the study by Maheu et al.58 e
which we have categorized as a high quality study (Table I),
and it presented detailed joint speciﬁc summary statistics
for both knee and hip OA patients after 6 months’ ASU treat-
ment. The observed post hoc calculated clinical improvement
with regard to pain reduction after 6 months’ ASU therapy cor-
responded to a signiﬁcant moderate to large clinical improve-
ment (ES¼ 0.69 [95% CI: 0.13e1.26]; P¼ 0.02) in hip
OA patients, whereas the borderline signiﬁcant improvement
in knee OA patients corresponded to a small to moderate ef-
ﬁcacy (ES¼ 0.35 [0.02e0.72]; P¼ 0.07). Compared to our
empirical prediction model, we interpret this contradictory
result as a consequence of having the only long-term study
(1 year) by Lequesne et al.63 providing the meta-analysis
model with the only 100% hip OA population. From a statistical
viewpoint, trial duration would be characterized as a detailed
trial feature (without any error around the estimate, as a conse-
quence of the original RCT study protocol); accordingly,
predictive inference based on meta-regression would be con-
sidered sufﬁcient26. Conversely, the clinical efﬁcacy joint in-
teraction might lead to a better statistical model on average
(i.e., reducing the between trial variability), whereas the pre-
dictive model most certainly calls for an IPD meta-analysis76.
In general, meta-regression e which we used e can be used
to estimate such interactions using detailed published data,
but it lacks statistical power, and is prone to bias, whereas
the use of IPD can improve estimation of such interactions,
among other beneﬁts, but it can be laborious to collect and
analyze77.
Supportive data of a disease-modifying anti-OA activity of
ASU have been presented in animal studies. A recent pla-
cebo-controlled animal study by Kawcak et al. evaluated
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Fig. 3. Meta-regression relations: ESs (ESpain, ESLequesne, and ORresponders) on the vertical axis are plotted against the %hip OA patients in-
cluded (A, C, and E) and trial duration (B, D, and F), respectively. Size of every circle is proportional to the precision of each efﬁcacy estimate.
The solid line indicates the predicted treatment magnitude and direction, whereas the dashed lines represent 95% CI using a REML based
model.
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mentally induced OA in 16 horses78. ASU extracts given
for 70 days had no effect on signs of pain or lameness;
however, there was a reduction in severity of articular car-
tilage erosion and synovial hemorrhage and increase in ar-
ticular cartilage glycosaminoglycan synthesis78. These
objective data lead the authors to conclude that the use
of ASU extracts might serve as a disease-modifying treat-
ment for management of OA in horses. Similarly, in an
ovine meniscectomy animal model an anabolic effect on
chondrocytes was demonstrated, resulting in the stimula-
tion of matrix production79.
The biochemical pathway associated with the possible
efﬁcacy of ASU in OA has not been clariﬁed. In a recent
paper by Gabay et al. the effect of ASU on chondrocyte
intracellular responses was examined, suggesting a novel
mechanism of ASU-mediated activity80. Their results indi-
cated that ASU might express a unique range of activities,
which could counteract deleterious processes involved in
OA, such as inﬂammation. However, as emphasized by
the authors more studies are needed to substantiate this
possible mode of action in a clinical setting. Since the
concentration of ASU in blood and synovial ﬂuid is not
known e and ASU is composed of different components e
the activity of the various components needs to be
determined before deﬁning the optimal ASU concentration
for future experiments80.
Oral non-steroidal anti-inﬂammatory drugs are widely
used in OA without proven long-term efﬁcacy81. In this
context, the results with ASU indicate a relevant clinical
effect with a short term, general ES larger than other
medica7, including paracetamol (acetaminophen)82. Four
domains e including joint imaging in long-term studies
(studies 1 year in duration) e have been identiﬁed as
core outcome measures21 that should be evaluated in
Phase III clinical trials of knee, hip, and hand OA22. Unfor-
tunately, only one of the included studies could be consid-
ered a long-term study in this respect63, the primary end
point in the study was a change of the joint space width
(JSW) on plain anteroposterior radiographs of the pelvis
in the standing position after 2 years’ treatment. The over-
all comparison of the evolution of JSW showed no diff-
erence between the ASU and placebo. However, in
a subgroup analysis with patients dichotomized according
to the median value of the baseline JSW, the joint space
loss in the most severely affected subgroup of patients
was signiﬁcantly greater in the placebo group than in
the ASU group. In the less severely affected subgroup
of patients the JSW decrease was identical with no differ-
ence in ASU and placebo groups63. The authors had no
explanation for this unexpected result of their post hoc
analysis.
The possibility of publication bias with a preference for
positive results cannot be excluded83. However, we found
no indication of congress abstracts not being published
(as a peer reviewed paper) and non-signiﬁcant results of
ASU have been published as well55,63. The total number
of studies included in the present meta-analysis seemed
too sparse to include a formal graphic test for publication
bias84,85. In our opinion, the most important limitation asso-
ciated with the present meta-analysis is the fact that all the
included studies were industry funded, which may augment
the risk of bias mentioned above: there is evidence sug-
gesting that trials funded by for-proﬁt organizations may
be more positive due to biased interpretation of trial
results86,87. Likewise, there is evidence that industry sup-
ported reviews of drugs should be read with caution asthey have more favorable conclusions than corresponding
Cochrane reviews88. We declare that we have no conﬂicts
of interest in regard to ASU and OA; this critical review
was initiated based on (local) medical considerations dis-
cussed in Denmark19.
As a conclusion of this meta-analysis, we suggest that
ASUs are no worse and no better for treatment of OA
than other medications. As there is no evidence of signif-
icant adverse effects of ASU, patients may be recommen-
ded to give ASU a chance for e.g., 3 months, after which
a balanced review of the individual effect is necessary.
The health professional should be aware that the com-
bined evidence behind such advice supports a better
chance of success in patients with knee OA than in those
with hip OA.Conﬂict of interest
None of the authors have anything to disclose.Acknowledgments
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To adjust simultaneously for both relevant covariates:
%hips affected and duration of trial, we combined these
two in the model, corresponding to a three-dimensional
analysis. These multivariate analyses48 can be illustrated
using a conditionally independent hierarchical (i.e., empiri-
cal Bayes [EB])47 modiﬁed meta-analysis forest-plot (see
Appendix ﬁgure)48. In the adjusted analyses we included
each original study’s characteristics (see Table I, %hips af-
fected and duration of trial) in the model, based on the mix-
ing distribution serving as a prior distribution, and resulting
in (conditional-) adjusted EB estimates for each study46e48.
Based on these adjusted estimates, it was evident that the
average patient would experience a small to moderate pain
reduction (ES¼ 0.40 [0.25e0.55]) after 6 months’ treatment
with ASU. Focusing on knee and hip joint separately, these
data indicate that knee OA patients would experience
a large clinical effect according to pain reduction (ES:
0.99 [0.54e1.44]). However, these theoretical estimates
would indicate that patients with hip OA might even experi-
ence increased pain after ASU treatment for 6 months (ES:
0.44 [1.05e0.17]). Similarly, the clinical efﬁcacy accord-
ing to the Lequesne index was evident, as the average pa-
tient experienced a close to moderate improvement (ES:
0.46 [0.27e0.64]). The joint speciﬁc efﬁcacy after 6 months’
treatment: knee joints showed a moderate to large clinical
improvement (ES: 0.65 [0.10e1.21]), whereas patients
with hip OA might experience less than a small clinical
effect, based on a non-signiﬁcant test (ES: 0.17
[0.57e0.92]). Finally, in regard to heterogeneity and post
hoc adjusted efﬁcacy, data indicated that the average pa-
tient is more likely to respond to treatment after ASU as
opposed to placebo therapy for 6 months (OR: 2.20
[1.60e3.02]), although this is only evident in knee OA pa-
tients (knee OA, ES: 2.60 [1.01e6.70] and hip OA, ES:
1.72 [0.48e6.17], respectively).
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